298
Participants
Start Date
March 22, 2024
Primary Completion Date
December 21, 2028
Study Completion Date
March 21, 2029
ACE-86225106 tablet
ACE-86225106 will be administered orally daily as a continuous regimen. Subjects will continue to receive study treatment until PD as judged by local investigator review, development of unacceptable toxicity, or withdrawal of consent.
RECRUITING
Chongqing Cancer Hospital, Chongqing
RECRUITING
Fujian Cancer Hospital, Fuzhou
RECRUITING
Sun Yat-Sen University Cancer Center, Guangzhou
RECRUITING
Henan Cancer Hospital, Zhengzhou
RECRUITING
Hubei Cancer Hospital, Wuhan
RECRUITING
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan
RECRUITING
Hunan Cancer Hospital, Changsha
RECRUITING
Jinan Central Hospital, Jinan
RECRUITING
Qilu Hospital Shangdong University, Jinan
RECRUITING
Fudan University Shanghai Cancer Center, Shanghai
RECRUITING
Second Hospital Affiliated to Shanxi Medical University, Taiyuan
RECRUITING
Zhejiang Cancer Hospital, Hangzhou
RECRUITING
First Hospital Affiliated to Wenzhou Medical University, Wenzhou
Acerand Therapeutics (Shanghai) Limited
INDUSTRY